$ADMA holding the 50-day moving average like a rock ($11.06) — 200-day EMA test at $11.82 coming up fast

Anyone else quietly accumulating $ADMA Biologics(ADMA)$ here around $11?

The stock got cut in half from its $20 peak earlier this year, but if you look at the actual business, it's printing cash. Gross margins are sitting at an absurd 69.4%, net leverage is down to basically 0.1x, and they're pulling in over $230M in annual EBITDA. ASCENIV is pacing toward a billion-dollar annual run rate, and you're getting all of this at 15.1x trailing earnings.

Technically, it just reclaimed both its 50-day SMA ($10.02) and 50-day EMA ($10.25). Every dip into $10.30–$10.50 gets vacuumed right up. Once we punch through the 200-day EMA around $11.82, there is basically no overhead volume until $14.

How I'm playing it:

  • Current: $11.06 – $11.33

  • Accumulation zone: $10.40 – $10.95

  • Stop loss: Daily close below $9.45

  • Targets: $11.82 first, then $14.20.

Are you guys playing the gap fill to $12+, or waiting for a cleaner breakout over $11.50?

# Trade Feed: Who is your favorite trader?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment(5)

  • Top
  • Latest
  • Daniel Stretton
    ·11-06 13:02
    If the payout is covered by cash flow, I'm comfortable holding equity exposure through the noise. Even a conservative 4.5% annualized return over 5 years changes the math on this considerably. I'll be wrong eventually; I just don't think it's this quarter.
    Reply
    Report
  • Ay Ling Yong
    ·11-06 13:05
    Price lost the level that mattered. I don't need a narrative to respect that. If growth comes in a point lower, the whole 26-year projection inverts.
    Reply
    Report
  • Liping Tee
    ·11-06 21:16
    [Strong][Strong]
    Reply
    Report
  • Tsuen Seng Koh
    ·11-06 21:15
    [Strong][Strong]
    Reply
    Report
  • Hong Na
    ·11-06 13:40
    [Strong][Strong]
    Reply
    Report